亿元索赔引爆GLP-1研发暗战！美迪西遭客户“反目”，CRO行业信任危机浮现

Core Viewpoint - The lawsuit between Medisci and Hongxu Biotech highlights the fragile trust relationship between pharmaceutical companies and outsourced service providers in the context of the booming GLP-1 drug development market [1][2]. Group 1: Lawsuit Details - The dispute originated from a 2020 technical service contract where Medisci was tasked with providing non-clinical safety evaluations for Hongxu Biotech's GLP-1/GIP dual-target new drug, HX-100101-1 [2]. - Hongxu Biotech accuses Medisci of serious breach of contract, seeking to terminate the contract, refund service fees of 5.018 million yuan, and claim damages totaling 1.515 billion yuan [2]. - The involved project received clinical trial approval in China in December 2023, but a sudden inspection by the National Medical Products Administration in March raised concerns about the authenticity of the data [2]. Group 2: Impact on Medisci - For Medisci, with annual revenue just over 1 billion yuan, the lawsuit represents a significant survival pressure test, as the potential payout exceeds its net profit for the first half of the year [3]. - The market reacted with a 4.69% increase in stock price on the day of the announcement, but underlying risks to industry trust and client relationships are evident [3]. - The lawsuit could lead to tighter payment terms from clients and delays in new orders, particularly affecting projects related to metabolic drugs [3]. Group 3: Financial Performance - Medisci's financial reports indicate ongoing losses for 2023-2024, but there are signs of recovery with a 3.64% increase in revenue to 540 million yuan in the first half of the year and a 31% increase in overseas revenue [4]. - The company achieved a turnaround in Q2, but prolonged litigation could jeopardize its hard-won profitability [4]. Group 4: Industry Implications - The dispute reveals underlying issues in the industry, particularly the aggressive timelines for safety evaluations that reflect a distorted pursuit of research efficiency [5]. - Although the authenticity of the application materials has not been confirmed, the inspection serves as a warning about the common lack of clarity in responsibilities within collaborations [5].